Page last updated: 2024-10-16

adenine and Neutropenia

adenine has been researched along with Neutropenia in 15 studies

Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.

Research Excerpts

ExcerptRelevanceReference
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)."2.90Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019)
"This was an open-label, multicenter, phase-1 study to evaluate the drug interaction between steady-state ibrutinib and moderate (erythromycin) and strong (voriconazole) CYP3A inhibitors in patients with B-cell malignancies and to confirm dosing recommendations."2.87A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. ( Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J, 2018)
"Ibrutinib combined with rituximab is active and well tolerated in patients with relapsed or refractory mantle cell lymphoma."2.82Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. ( Addison, A; Badillo, M; Champlin, R; Chen, W; Chuang, H; DeLa Rosa, M; Fayad, L; Hagemeister, F; Lam, L; Lee, H; Li, S; Medeiros, LJ; Nomie, K; Oki, Y; Romaguera, J; Samaniego, F; Santos, D; Turturro, F; Wagner-Bartak, N; Wang, ML; Westin, J; Young, KH; Zhang, H; Zhang, L; Zhao, D, 2016)
"Between Sept 19, 2012, and Jan 21, 2014, 578 eligible patients were randomly assigned to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group)."2.82Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. ( Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D, 2016)
"Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year."2.75Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (80.00)24.3611
2020's3 (20.00)2.80

Authors

AuthorsStudies
Ruchlemer, R1
Ben-Ami, R1
Bar-Meir, M1
Brown, JR1
Malphettes, M1
Mous, R1
Tonino, SH1
Soussain, C1
Barzic, N1
Messina, JA1
Jain, P1
Cohen, R1
Hill, B1
Mulligan, SP1
Nijland, M1
Herishanu, Y1
Benjamini, O1
Tadmor, T1
Okamoto, K1
Arthurs, B1
Gottesman, B1
Kater, AP1
Talha, M1
Eichhorst, B1
Korem, M1
Bogot, N1
De Boer, F1
Rowe, JM1
Lachish, T1
Byrd, JC4
Furman, RR3
Coutre, SE3
Flinn, IW1
Burger, JA4
Blum, K1
Sharman, JP1
Wierda, W2
Zhao, W2
Heerema, NA3
Luan, Y1
Liu, EA1
Dean, JP2
O'Brien, S2
Rogers, KA1
Huang, Y1
Ruppert, AS1
Abruzzo, LV1
Andersen, BL1
Awan, FT1
Bhat, SA1
Dean, A1
Lucas, M1
Banks, C1
Grantier, C1
Lozanski, G1
Maddocks, KJ1
Valentine, TR1
Weiss, DM1
Jones, JA2
Woyach, JA1
Zhou, Z1
Zhang, L2
Wang, X2
Li, X1
Li, L1
Fu, X1
Zhang, X1
Li, Z1
Sun, Z1
Zhang, M1
Sinha, R1
Redekop, WK1
Ujjani, C1
Wang, H1
Skarbnik, A1
Trivedi, N1
Ramzi, P1
Khan, N1
Cheson, BD1
de Jong, J1
Hellemans, P1
De Wilde, S1
Patricia, D1
Masterson, T1
Manikhas, G1
Myasnikov, A1
Osmanov, D1
Córdoba, R1
Panizo, C1
de Zwart, L1
Snoeys, J1
Chauhan, V1
Jiao, J1
Sukbuntherng, J1
Ouellet, D1
Jain, N1
Keating, M1
Thompson, P1
Ferrajoli, A1
Burger, J1
Borthakur, G1
Takahashi, K1
Estrov, Z1
Fowler, N1
Kadia, T1
Konopleva, M1
Alvarado, Y1
Yilmaz, M1
DiNardo, C1
Bose, P1
Ohanian, M1
Pemmaraju, N1
Jabbour, E1
Sasaki, K1
Kanagal-Shamanna, R1
Patel, K1
Jorgensen, J1
Garg, N1
Sondermann, K1
Cruz, N1
Wei, C1
Ayala, A1
Plunkett, W1
Kantarjian, H1
Gandhi, V1
Hillmen, P2
Barrientos, JC1
Barr, PM2
Devereux, S2
Robak, T2
Kipps, TJ2
Schuh, A2
Moreno, C1
O'Dwyer, M2
Ghia, P2
Valentino, R1
Chang, S1
James, DF3
O'Brien, SM1
Blum, KA1
Coleman, M1
Wierda, WG1
Johnson, AJ1
Shaw, Y1
Bilotti, E1
Zhou, C1
Tedeschi, A1
Owen, C1
Bairey, O1
Bartlett, NL2
Li, J1
Simpson, D1
Grosicki, S2
McCarthy, H1
Coutre, S1
Quach, H1
Gaidano, G1
Maslyak, Z1
Stevens, DA1
Janssens, A2
Offner, F1
Mayer, J2
Hellmann, A1
Siddiqi, T1
Polliack, A1
Tam, CS1
Suri, D1
Cheng, M1
Clow, F1
Styles, L1
Wang, ML1
Lee, H1
Chuang, H1
Wagner-Bartak, N1
Hagemeister, F1
Westin, J1
Fayad, L1
Samaniego, F1
Turturro, F1
Oki, Y1
Chen, W1
Badillo, M1
Nomie, K1
DeLa Rosa, M1
Zhao, D1
Lam, L1
Addison, A1
Zhang, H1
Young, KH1
Li, S1
Santos, D1
Medeiros, LJ1
Champlin, R1
Romaguera, J1
Chanan-Khan, A1
Cramer, P1
Demirkan, F1
Fraser, G1
Silva, RS1
Pristupa, A1
Dilhuydy, MS1
Pylypenko, H1
Loscertales, J1
Avigdor, A1
Rule, S1
Villa, D1
Samoilova, O1
Panagiotidis, P1
Goy, A1
Mato, A1
Pavlovsky, MA1
Karlsson, C1
Mahler, M1
Salman, M1
Sun, S1
Phelps, C1
Balasubramanian, S1
Howes, A1
Hallek, M1
Link, CS1
Teipel, R1
Heidenreich, F1
Rücker-Braun, E1
Schmiedgen, M1
Reinhardt, J1
Oelschlägel, U1
von Bonin, M1
Middeke, JM1
Muetherig, A1
Trautmann-Grill, K1
Platzbecker, U1
Bornhäuser, M1
Schetelig, J1
Mugyenyi, P3
Walker, AS2
Hakim, J3
Munderi, P2
Gibb, DM2
Kityo, C2
Reid, A2
Grosskurth, H3
Darbyshire, JH3
Ssali, F2
Bray, D2
Katabira, E3
Babiker, AG1
Gilks, CF1
Kabuye, G1
Nsibambi, D2
Kasirye, R1
Zalwango, E1
Nakazibwe, M1
Kikaire, B1
Nassuna, G1
Massa, R1
Fadhiru, K2
Namyalo, M1
Zalwango, A1
Generous, L1
Khauka, P2
Rutikarayo, N1
Nakahima, W1
Mugisha, A1
Todd, J1
Levin, J1
Muyingo, S1
Ruberantwari, A1
Kaleebu, P2
Yirrell, D2
Ndembi, N2
Lyagoba, F2
Hughes, P1
Aber, M1
Lara, AM2
Foster, S2
Amurwon, J2
Wakholi, BN2
Whitworth, J1
Wangati, K1
Amuron, B1
Kajungu, D1
Nakiyingi, J1
Omony, W1
Tumukunde, D1
Otim, T1
Kabanda, J1
Musana, H1
Akao, J1
Kyomugisha, H1
Byamukama, A1
Sabiiti, J1
Komugyena, J1
Wavamunno, P1
Mukiibi, S1
Drasiku, A1
Byaruhanga, R1
Labeja, O1
Katundu, P2
Tugume, S2
Awio, P1
Namazzi, A1
Bakeinyaga, GT1
Katabira, H1
Abaine, D1
Tukamushaba, J1
Anywar, W1
Ojiambo, W1
Angweng, E1
Murungi, S2
Haguma, W1
Atwiine, S1
Kigozi, J3
Namale, L1
Mukose, A1
Mulindwa, G1
Atwiine, D1
Muhwezi, A1
Nimwesiga, E1
Barungi, G1
Takubwa, J1
Mwebesa, D1
Kagina, G1
Mulindwa, M1
Ahimbisibwe, F1
Mwesigwa, P1
Akuma, S1
Zawedde, C1
Nyiraguhirwa, D1
Tumusiime, C1
Bagaya, L1
Namara, W1
Karungi, J1
Kankunda, R1
Enzama, R1
Latif, A2
Robertson, V2
Chidziva, E1
Bulaya-Tembo, R1
Musoro, G1
Taziwa, F1
Chimbetete, C1
Chakonza, L1
Mawora, A1
Muvirimi, C1
Tinago, G1
Svovanapasis, P1
Simango, M1
Chirema, O1
Machingura, J1
Mutsai, S1
Phiri, M1
Bafana, T1
Chirara, M2
Muchabaiwa, L2
Muzambi, M2
Mutowo, J1
Chivhunga, T1
Chigwedere, E1
Pascoe, M1
Warambwa, C1
Zengeza, E1
Mapinge, F1
Makota, S1
Jamu, A1
Ngorima, N1
Chirairo, H1
Chitsungo, S1
Chimanzi, J1
Maweni, C1
Warara, R1
Matongo, M1
Mudzingwa, S1
Jangano, M1
Moyo, K1
Vere, L1
Mdege, N1
Machingura, I1
Ronald, A1
Kambungu, A1
Lutwama, F1
Mambule, I1
Nanfuka, A1
Walusimbi, J1
Nabankema, E1
Nalumenya, R1
Namuli, T1
Kulume, R1
Namata, I1
Nyachwo, L1
Florence, A1
Kusiima, A1
Lubwama, E1
Nairuba, R1
Oketta, F1
Buluma, E1
Waita, R1
Ojiambo, H1
Sadik, F1
Wanyama, J1
Nabongo, P1
Oyugi, J1
Sematala, F1
Muganzi, A1
Twijukye, C1
Byakwaga, H1
Ochai, R1
Muhweezi, D1
Coutinho, A1
Etukoit, B1
Gilks, C2
Boocock, K1
Puddephatt, C1
Grundy, C1
Bohannon, J1
Winogron, D1
Burke, A1
Babiker, A2
Wilkes, H1
Rauchenberger, M1
Sheehan, S1
Spencer-Drake, C1
Taylor, K1
Spyer, M1
Ferrier, A1
Naidoo, B1
Dunn, D2
Goodall, R2
Peto, L1
Nanfuka, R1
Mufuka-Kapuya, C1
Pillay, D1
McCormick, A1
Weller, I1
Bahendeka, S1
Bassett, M1
Wapakhabulo, AC1
Gazzard, B1
Mapuchere, C1
Mugurungi, O1
Burke, C1
Jones, S1
Newland, C1
Pearce, G1
Rahim, S1
Rooney, J1
Smith, M1
Snowden, W1
Steens, JM1
Breckenridge, A1
McLaren, A1
Hill, C1
Matenga, J1
Pozniak, A1
Serwadda, D1
Peto, T1
Palfreeman, A1
Borok, M1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069]Phase 2199 participants (Actual)Interventional2010-06-30Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]Phase 1/Phase 2133 participants (Actual)Interventional2010-05-31Completed
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451]Phase 1/Phase 287 participants (Actual)Interventional2015-08-03Active, not recruiting
A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma[NCT05014100]Phase 255 participants (Anticipated)Interventional2021-09-01Not yet recruiting
A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL[NCT02200848]Phase 15 participants (Actual)Interventional2014-04-30Terminated (stopped due to Recruitment difficulties and toxicity)
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)[NCT02756897]Phase 2234 participants (Actual)Interventional2016-07-07Active, not recruiting
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]Phase 3391 participants (Actual)Interventional2012-06-30Completed
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346]Phase 3232 participants (Actual)Interventional2012-08-28Completed
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487]Phase 3269 participants (Actual)Interventional2013-03-31Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]40 participants (Actual)Observational2017-07-21Active, not recruiting
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097]Phase 215 participants (Anticipated)Interventional2022-10-30Not yet recruiting
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]40 participants (Actual)Observational [Patient Registry]2018-12-01Completed
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]Phase 322 participants (Actual)Interventional2019-12-09Active, not recruiting
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL[NCT01880567]Phase 2113 participants (Actual)Interventional2013-07-15Active, not recruiting
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic[NCT01611090]Phase 3578 participants (Actual)Interventional2012-09-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Event

All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276542

Number of Subjects With Adverse Events

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH199

Progressive Disease (PD)

A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276570

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention (Number)
Food Effect Cohort1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

InterventionParticipants (Number)
PCI-32765116
Food Effect11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive71
Relapsed/ Refractory75.3
Food Effect56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive96.3
Relapsed/ Refractory73.6
Food- EffectNA

OS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)65.1
Ibrutinib (Arm B)67.7

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)4.1
Ibrutinib (Arm B)42.6

Overall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)22.4
Ibrutinib (Arm B)87.7

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)NA

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)44.1

Rate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

,
Interventionpercentage of participants (Number)
Hgb Improvement in patient with baseline anemiaPlatelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)69.778.4
Ofatumumab (Arm A)32.69.4

ORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Interventionpercentage of participants (Number)
Ibrutinib82.4
Chlorambucil35.3

Overall Survival (OS)

OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
ChlorambucilNA

PFS (Progression Free Survival)

"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
Chlorambucil18.9

Proportion of Sustained Hemoglobin Improvement

The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib45.6
Chlorambucil20.3

Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib84.3
Chlorambucil45.5

Proportion of Sustained Platelet Improvement

The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib27.2
Chlorambucil11.3

Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib77.1
Chlorambucil42.9

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)

Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported. (NCT01611090)
Timeframe: Baseline to EOT (Up to 2 years)

Interventionmilligram per liter (mg/L) (Mean)
Ibrutinib+BR-0.46
Placebo+BR-0.23

Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment

"EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from 1 = not at all to 4 = very much. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from 1 = very poor to 7 = excellent. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms." (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-2.1
Placebo+BR-4.1

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment

The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility. (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR0.0
Placebo+BR0.0

Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment

The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-4.3
Placebo+BR4.0

Change From Baseline in FACIT-Fatigue Scale at End of Treatment

FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

InterventionUnits on a scale (Mean)
Ibrutinib+BR-0.9
Placebo+BR0.0

Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale

Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5-point categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). (NCT01611090)
Timeframe: Up to 2 years

InterventionMonths (Number)
Ibrutinib+BR6.5
Placebo+BR4.6

Number of Participants Who Received Subsequent Antineoplastic Therapy

Number of participants who received subsequent antineoplastic therapy was reported. (NCT01611090)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Ibrutinib+BR52
Placebo+BR61

Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia. (NCT01611090)
Timeframe: From the date of randomization to disease progression (Up to 2 years)

InterventionParticipants (Count of Participants)
Ibrutinib+BR0
Placebo+BR0

Overall Response Rate (ORR)

ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils >1.5*10^9/liter (L), platelets >100*10^9/L, Hgb >11 gram per deciliter (g/dL) and absolute lymphocyte count <4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: >=50% decrease in ALC, >=50% decrease in sum products of up to 6 lymph nodes, >=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils >1.5*10^9/L, Platelets >100*10^9/L and Hgb>11 g/dL or >=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR87.2
Placebo+BR66.1

Overall Survival (OS)

OS was defined as the interval between the date of randomization and the date of death from any cause. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BRNA
Placebo+BRNA

Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response

MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders. (NCT01611090)
Timeframe: Up to 5 years

InterventionPercentage of participants (Number)
Ibrutinib+BR28.7
Placebo+BR5.9

Progression-free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes >1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); >=50% increase in existing lymph nodes; >=50% increase in enlargement of liver or spleen; >=50% increase from baseline in lymphocyte count (and to >=5*10^9/L) or >=50% increase from nadir count confirmed on >=2 serial assessments if absolute lymphocyte count (ALC) >=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology. (NCT01611090)
Timeframe: Up to 5 years

InterventionMonths (Median)
Ibrutinib+BR65.12
Placebo+BR14.32

Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment

The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much). (NCT01611090)
Timeframe: Baseline to EOT (up to 2 years)

,
InterventionUnits on the scale (Mean)
Lost weightDry mouthBruisesAbdominal discomfortTemperature going up and downNight sweatsSkin problemsFeel illFeel lethargicFelt slowed downLimited in planning activitiesWorried about health in the futureTrouble with chest infectionsTrouble with other infectionsRepeated courses of antibioticsWorried about picking up infection
Ibrutinib+BR0.10.30.10.10.1-0.60.40.10.10.30.20.00.20.70.90.3
Placebo+BR0.00.10.00.00.0-0.30.30.20.00.00.10.00.00.10.00.2

Percentage of Participants With Sustained Hematologic Improvement

Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (>)100* 109/liter (L) if baseline less than or equal to (<=) 100*109/L or increase >= 50 percent (%) over baseline; 2) Hemoglobin >11 gram per deciliters (g/dL) if baseline <= 11 g/dL or increase >= 2 g/dL over baseline. (NCT01611090)
Timeframe: Up to 5 years

,
InterventionPercentage of Participants (Number)
HemoglobinPlatelets
Ibrutinib+BR36.730.8
Placebo+BR29.121.8

Trials

10 trials available for adenine and Neutropenia

ArticleYear
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival;

2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-01, Volume: 38, Issue:31

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2020
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Blood advances, 2018, 04-10, Volume: 2, Issue:7

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female;

2018
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:12

    Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco

2018
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    The New England journal of medicine, 2019, 05-30, Volume: 380, Issue:22

    Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillatio

2016
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    The Lancet. Oncology, 2016, Volume: 17, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atr

2016
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea

2010

Other Studies

5 other studies available for adenine and Neutropenia

ArticleYear
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
    Mycoses, 2019, Volume: 62, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Immunocompromised Host; Invasive Fungal Inf

2019
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Annals of hematology, 2021, Volume: 100, Issue:6

    Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Het

2021
Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:2

    Topics: Adenine; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chlorambucil; Comor

2018
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
    Bone marrow transplantation, 2016, Volume: 51, Issue:6

    Topics: Adenine; Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neu

2016